In surprise result, Alzheimer’s drug from Eisai, Biogen shows benefit in large trial

The companies said the drug, called lecanemab, met all of its goals in the Phase 3 study. The data are a significant finding and provide stronger support for a much-debated hypothesis for treating Alzheimer’s.